Loading articles…
Loading articles…
Research included in this condition report
16 rights-cleared articles published in 2025, ordered newest first.
16 articles from 2025
Newest firstBackground Patients with Inflammatory bowel disease (IBD) often seek alternative therapies for symptom management. This study investigates the perceptions, consumption patterns, and reported outcomes of cannabis and cannabidiol (CBD) oil use among IBD patients and controls. Methods A 37-question survey was administered to 139 participants (IBD patients, n = 93; control/non-IBD participants, n = 33) to assess usage…
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder marked by persistent gastrointestinal inflammation and a spectrum of systemic effects, including extraintestinal manifestations (EIMs) that impact the joints, skin, liver, and eyes. Conventional therapies primarily target intestinal inflammation, yet they frequently fail to ameliorate these systemic complications. Recent investigations…
This review examines the impact of interactions between the gut microbiota and the endocannabinoidome (eCBome) on health and disease, highlighting their significance for physiological and pathological processes. We identify key research gaps and challenges to advance the field. The review discusses the role of dietary patterns and physical activity in regulating these interactions. It also explores the complex nat…
Background The use of Cannabis sativa L. (Cannabis) was reported by observational studies on inflammatory bowel diseases (IBD) patients. However, this indication is poorly supported by clinical trials. Several pre-clinical studies demonstrated the anti-inflammatory activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD) at intestinal level. On the contrary, minor cannabinoids, such as cannabigerol (CBG)…
Background Patients with inflammatory bowel disease (IBD) often experience symptoms refractory to available treatments, prompting the use of alternative therapies like cannabis. Previous studies have shown cannabis users require higher levels of sedation for procedures. The anti-inflammatory effects of cannabis have been studied with mixed conclusions. We aimed to investigate if patients with IBD who reported cann…
Objectives Stress is associated with inflammatory bowel disease (IBD) development and exacerbation. We evaluated the impact of the war in Gaza on Israeli IBD patients and related barriers to IBD care. Methods Adult IBD patients were blindly enrolled to complete a patient-reported-outcome electronic questionnaire assessing symptoms, hospitalizations, medications, psychosocial factors, economic issues, and adherence…
Background/Objectives: Current inflammatory bowel disease (IBD) treatments focus on symptomatic relief, highlighting the need for innovative approaches. Dysregulation of the cannabinoid 1 (CB1) receptor, part of the endocannabinoid system, is linked to colitis. While tetrahydrocannabinol (THC) alleviates colitis via CB1 activation, its psychotropic effects limit clinical use. ZCZ011, a CB1R allosteric modulator, a…
Macrophages play a crucial role in maintaining intestinal homeostasis and can exhibit either pro-inflammatory M1 or anti-inflammatory M2 phenotypes. The cannabinoid receptor type 2 (CB2) is involved in immune regulation and may represent a therapeutic target in inflammatory bowel disease (IBD). Our study investigates the phenotype of circulating macrophages and CB2 expression in children with IBD, assessing the ro…
Intestinal fibrosis is a common and serious complication of inflammatory bowel diseases, often leading to strictures that require endoscopic or surgical intervention. Despite advances in anti-inflammatory therapies, effective antifibrotic treatments is currently not available. Therefore, new treatment methods for intestinal fibrosis are sought with the endocannabinoid system (ECS) as a potential therapeutic target…
Current therapies for inflammatory bowel disease (IBD), such as olsalazine and cyclosporine, often exhibit limited long-term efficacy and are associated with adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, shows promise for its anti-inflammatory properties, though its effectiveness as a monotherapy remains inconclusive. This study investigates the therapeutic potential of combining low-dos…
Background and aims Intestinal fibrosis, a frequent complication of inflammatory bowel disease, is characterized by stricture formation with no pharmacological treatment to date. N-acylethanolamine acid amidase (NAAA) is responsible for the hydrolysis of acylethanolamides (AEs, eg, palmitoylethanolamide and oleoylethanolamide). Here, we investigated NAAA and AE signaling in gut fibrosis. Methods NAAA and AE signal…
Visceral Pain is a common debilitating symptom of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The endocannabinoid system (ECS) is a prime target for alleviation of visceral pain, given its important role in both gastrointestinal physiology and pain. We will conduct a systematic review of randomised controlled trials (RCTs) of cannabis, cannabinoids, cannabis-based medicines (CBMs), and oth…
ObjectiveTo identify post-marketing adverse event (AE) signals associated with isotretinoin using real-world data from the U.S. Food and Drug Administration (FDA) AE Reporting System (FAERS), aiming to provide references for clinical safety and further research. MethodsAE reports from the first quarter of 2004 to the third quarter of 2024 were extracted from the FAERS database. Four signal detection methods were e…
The ability to accurately predict the dynamic evolution of microbial communities is critical for advancing personalized medicine, precision intervention, and ecological system management. However, the irregular sampling, high missingness, and complex temporal behaviors that characterize longitudinal microbiome datasets present substantial challenges to reliable forecasting. Here we propose MicroProphet, a personal…
BackgroundThis paper investigates a patient-led approach to research on wellbeing in individuals with Inflammatory Bowel Disease (IBD). Traditionally, Public and Patient Involvement (PPI) groups have contributed to the design of clinical research but less often to the analysis and reporting of findings. This study is wholly led by a patient group with no direct input from clinicians, thus presenting an entirely no…
ImportanceHidradenitis suppurativa (HS) has been associated with spondyloarthritis (SpA) and inflammatory bowel disease (IBD) and proposed as a potential manifestation of these conditions. However, the relative rarity of HS, combined with the diverse methodologies used in previous studies, leaves several uncertainties surrounding its epidemiology within this disease spectrum. ObjectiveTo describe the prevalence an…